Antipsychotic stewardship: 'right drug, right dose, right duration'

The word "stewardship" entered medicine through antibiotics, where the cost of careless use is resistance, infection, and death. Antipsychotics carry different costs — metabolic disease, movement disorders, sedation, lost years of function — but the idea translates cleanly. Antipsychotic stewardship means using the right drug at the right dose for the right duration with the right monitoring, and reconsidering each of those choices on a regular schedule. It is not anti-medication. It is the opposite of careless prescribing — the careful version.

Why stewardship matters

Two patterns drive most of the harm from antipsychotic over-use:

• Off-label prescribing without clear indication: antipsychotics are sometimes prescribed for insomnia, mild anxiety, or behavioral symptoms in dementia where the evidence for benefit is weak and the side effect burden real
• Dose creep and polypharmacy: doses are increased during difficult periods and rarely titrated back; second antipsychotics are added without removing the first

Major guidelines — the APA practice guideline for schizophrenia, the NICE guideline on psychosis and schizophrenia, the WHO mhGAP intervention guide — all converge on the same principles. Stewardship is the operationalization.

The five questions of antipsychotic stewardship

1. Is an antipsychotic indicated?

For schizophrenia, schizoaffective disorder, bipolar I, and a defined list of other indications, yes. For insomnia alone, generalized anxiety alone, mild depression alone, or behavioral symptoms in dementia without a clear safety crisis, the answer is often no — or at least "not first." The first stewardship question is always: would this patient be better served by a different intervention?

2. Is this the right drug?

Choice between agents should reflect:

• The patient's symptom profile (positive symptoms, negative symptoms, mood features)
• Side effect tolerability (metabolic, sedation, EPS, prolactin, sexual)
• Comorbid medical conditions (cardiac, metabolic, hepatic)
• Past response history
• Available administration routes (oral, LAI)
• Cost and access

The "best" antipsychotic is the one that fits the patient. See our best-medication article.

3. Is this the right dose?

The lowest dose that achieves and maintains response. Many patients are on doses higher than they need because doses were raised during a difficult period and never reduced. Periodic reassessment of whether the same control could be achieved at a lower dose is part of stewardship.

4. Is this the right duration?

For schizophrenia, long-term treatment is usually needed. For brief psychotic disorder or substance-induced psychosis, treatment may be time-limited. For autism-related irritability or off-label uses, time limits and review dates should be defined at the start. The phrase "lifetime maintenance" should be earned through clinical reasoning, not assumed by default.

5. Is the monitoring right?

• Baseline and periodic metabolic labs (glucose, A1c, lipids, weight, BMI, blood pressure)
• AIMS exam at least annually for movement side effects
• Prolactin when symptoms suggest hyperprolactinemia or with high-prolactin agents
• ECG when using QT-prolonging agents or with cardiac comorbidity
• CBC for clozapine on the FDA-required schedule
• Liver function with hepatotoxic agents

If the prescriber is not doing standard monitoring, a respectful patient request usually fixes it.

The polypharmacy problem

Antipsychotic polypharmacy — using two or more antipsychotics at the same time — is common and rarely supported by evidence. Most guidelines recommend monotherapy except in defined situations: brief overlap during a switch, augmentation of clozapine for treatment-resistant cases, or specific combinations with an evidence base. The most common reason for accidental polypharmacy is forgetting to stop the original medication when starting a new one. A stewardship lens catches this on review.

The dose-creep problem

A common pattern: a patient is stable on 4 mg of risperidone. They have a difficult month — work stress, a fight with a partner, a poor night's sleep — and the dose is raised to 6 mg. The difficulty passes, the patient stabilizes, the dose stays at 6 mg. A year later they are on 6 mg "because that is what is working." Stewardship would prompt a deliberate reassessment: could this patient now do well on 4 mg again? Sometimes yes, sometimes no — but the question should be asked.

Deprescribing as a positive practice

Reducing or stopping medication that is no longer needed is part of good prescribing, not a failure of it. The Canadian Deprescribing Network and similar groups have built tools and protocols. For antipsychotics, deprescribing should always be done slowly, with monitoring, and with a written re-engagement plan. See our tapering article.

Off-label prescribing: a stewardship perspective

Off-label use is sometimes appropriate — clinical practice runs ahead of FDA labeling in many areas. The stewardship test is not "is it on-label" but:

• Is there a defensible evidence base, even if not formal FDA approval?
• Have first-line treatments been tried?
• Has the patient been told it is off-label and given informed consent?
• Is there a clear plan to evaluate response and consider stopping if it does not work?

Stewardship in dementia

One of the largest stewardship issues globally is antipsychotic use in nursing homes for behavioral symptoms of dementia. The CMS in the US, the NICE in the UK, and similar bodies internationally have explicit campaigns to reduce inappropriate antipsychotic use in this population. The boxed warning about increased mortality in dementia patients is the floor, not the ceiling — non-pharmacological approaches should usually come first. See our antipsychotics in older adults article.

Patient-side stewardship

Stewardship is not only the prescriber's job. Patients can ask:

• "Why this medication?"
• "What is the target dose?"
• "How long do you anticipate I will be on it?"
• "What monitoring will we do?"
• "When will we revisit whether the dose can be lowered?"

A prescriber who welcomes these questions is practicing stewardship. A prescriber who does not is doing something else.

What good prescribing looks like

The hallmarks of antipsychotic stewardship in practice:

• The indication is documented and current
• The dose is the lowest that maintains response
• Monotherapy is the default, with combinations justified explicitly
• Monitoring labs are done on schedule
• Side effects are asked about, not waited for
• The patient is part of the conversation, not the recipient of decisions
• The medication plan is reviewed at every visit, not just at major events

The big picture

Antipsychotic stewardship is what mature psychiatric prescribing looks like. It is neither the reflexive "more medication is the answer" of an under-resourced clinic nor the reflexive "less medication is the answer" of an anti-psychiatry stance. It is the patient and prescriber asking the same questions together, on a regular schedule, and being willing to act on the answers. Done well, it produces better outcomes, fewer side effects, more patient trust, and a more sustainable long-term treatment relationship. Done badly — or not at all — it produces the all-too-familiar pattern of escalating doses, accumulating side effects, and quiet patient discontinuation.

For more, see shared decision-making, finding the right medication, and polypharmacy in schizophrenia.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.